Supplementary materials for the consolidated results for the second quarter (interim) of fiscal 2026. Consolidated net sales were 89,897 million yen, an increase of 14,?% year-over-year (there are unclear parts in the source regarding the year-over-year figure). The breakdown by domestic and China businesses and sales trends for 129 prescription Kampo formulations are disclosed. Notes on the impact of consolidating the Shanghai subsidiary and PPA-related considerations are included.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4540","jir_company_name":"Tsumura & Co.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4540-20261109-02.pdf","jir_short_summary":"Supplementary materials for the consolidated results for the second quarter (interim) of fiscal 2026. Consolidated net sales were 89,897 million yen, an increase of 14,?% year-over-year (there are unclear parts in the source regarding the year-over-year figure). The breakdown by domestic and China businesses and sales trends for 129 prescription Kampo formulations are disclosed. Notes on the impact of consolidating the Shanghai subsidiary and PPA-related considerations are included.","jir_summary":"### Performance Overview\nTsumura & Co. released supplementary materials for its consolidated results for the second quarter (interim) of fiscal 2026. Net sales were 89,897 million yen, showing a substantial increase compared with the same period last year; operating income was 17,119 million yen and net income attributable to owners of parent was 12,477 million yen, both increased. Contributions from the domestic business and the China business are shown; the China business exhibited phases of slowdown and re-expansion, while overall margin improvement is notable. The impact of consolidating Yomeishu Seizo is noted.\n\n### Impact on Shareholders and Notes\nDue attention is required when comparing financial statements due to the consolidation of Yomeishu Seizo. Trends in the sales composition ratio should be reviewed, particularly changes in the ratios of the domestic and China businesses. Note that amounts finalized after PPA may affect full-year forecasts. Cash and cash equivalents at the end of the period increased, which can be interpreted as indicating sound liquidity.","jir_financial_highlights":"Net Sales: 89,897 (YoY +13,543 \/ +15.1%)\nOperating Income: 17,119 (YoY +1,728 \/ +10.1%)\nNet Income Attributable to Owners of Parent: 12,477 (YoY +3,725 \/ +29.9%)\nCash and Cash Equivalents at End of Period: 91,582","jir_category":"","jir_hashtags":"#NotRelatedToShareBuyback, #SupplementaryFinancialMaterials","jir_key_figures":"Net Sales: 89,897 million yen (YoY increase)\nOperating Income: 17,119 million yen (YoY increase)\nNet Income Attributable to Owners of Parent: 12,477 million yen (YoY increase)","jir_meta_title":"Tsumura & Co. Supplementary Financial Materials | Fiscal 2026 Q2 Performance Highlights","jir_meta_description":"Key points from Tsumura & Co.'s supplementary materials for fiscal 2026 Q2. Net sales 89,897 million yen, operating income 17,119 million yen, net income 12,477 million yen. Summarizes the impact of consolidating Yomeishu Seizo, segment trends, and changes in cash balances for investors.","jir_og_title":"Tsumura & Co. Supplementary Financial Materials | Fiscal 2026 Q2 Performance Highlights","jir_og_description":"Key points from Tsumura & Co.'s supplementary materials for fiscal 2026 Q2, summarizing sales and profit trends, the status of domestic and China businesses, and the increase in cash balances relevant to investment decisions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8172,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144388","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n